@LucretiousNoticed you're very active in biotech companies. Maybe RAD is worth taking a look. Still think its a long way from anything worthwhile, but with Lantheus increasing its stake at a premium when its reaching all time lows could be a multi bagger from its all time lows.
Big risk though, its gone from mid 10c to as low as 2c in a span of two years.
Something could be brewing though - whether its a takeover or a genuine good drug candidate.
Sp was at mid 2c last week, and fridays ann was that Lantheus (6.7$B biotech) has taken a ~12% stake with a 6c placement for 8 million AUD, as well as funding their p1 clinical trial (significant reduction in possible cashburn).
Around $40 million in cash as per last quarterly (with burn rate of 13million per quarter)
T20 is 74% (64% Institutions + 10% Board) and probably more now after this raise.
Would say for anyone considering this, its definitely a massive gamble its trading near 52 weeks low before friday's announcement and has basically been in freefall since IPO. The SOI is about 2.1 billion so the churn would be massive even if there is a good announcement. It's only been flagged as I believe it could end up being a possible take over target.
